CN1278731C - Compound bupleurum root medicinal preparation - Google Patents
Compound bupleurum root medicinal preparation Download PDFInfo
- Publication number
- CN1278731C CN1278731C CN 200410065122 CN200410065122A CN1278731C CN 1278731 C CN1278731 C CN 1278731C CN 200410065122 CN200410065122 CN 200410065122 CN 200410065122 A CN200410065122 A CN 200410065122A CN 1278731 C CN1278731 C CN 1278731C
- Authority
- CN
- China
- Prior art keywords
- bupleurum root
- medicinal preparation
- preparation according
- root medicinal
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 43
- 241000202726 Bupleurum Species 0.000 title claims abstract description 39
- 239000000284 extract Substances 0.000 claims abstract description 60
- 239000003814 drug Substances 0.000 claims abstract description 52
- 239000007788 liquid Substances 0.000 claims abstract description 17
- 239000007902 hard capsule Substances 0.000 claims abstract description 13
- 239000006187 pill Substances 0.000 claims abstract description 12
- 239000007901 soft capsule Substances 0.000 claims abstract description 12
- 238000002347 injection Methods 0.000 claims abstract description 9
- 239000007924 injection Substances 0.000 claims abstract description 9
- 239000003826 tablet Substances 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims description 45
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 27
- -1 polyoxyethylene monostearate Polymers 0.000 claims description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- 229920002472 Starch Polymers 0.000 claims description 14
- 239000008107 starch Substances 0.000 claims description 14
- 235000019698 starch Nutrition 0.000 claims description 14
- 239000008187 granular material Substances 0.000 claims description 13
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 11
- 239000002202 Polyethylene glycol Substances 0.000 claims description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 239000006196 drop Substances 0.000 claims description 9
- 239000012046 mixed solvent Substances 0.000 claims description 9
- 239000011230 binding agent Substances 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 8
- 239000000080 wetting agent Substances 0.000 claims description 8
- 241000196324 Embryophyta Species 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 239000003381 stabilizer Substances 0.000 claims description 7
- 239000000341 volatile oil Substances 0.000 claims description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 239000004359 castor oil Substances 0.000 claims description 6
- 235000019438 castor oil Nutrition 0.000 claims description 6
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 6
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 6
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 6
- 229920000136 polysorbate Polymers 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 239000006184 cosolvent Substances 0.000 claims description 5
- 229920005862 polyol Polymers 0.000 claims description 5
- 239000005995 Aluminium silicate Substances 0.000 claims description 4
- 239000004368 Modified starch Substances 0.000 claims description 4
- 229920000881 Modified starch Polymers 0.000 claims description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 4
- 239000000783 alginic acid Substances 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 229960001126 alginic acid Drugs 0.000 claims description 4
- 150000004781 alginic acids Chemical class 0.000 claims description 4
- 235000012211 aluminium silicate Nutrition 0.000 claims description 4
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 claims description 4
- 229950005162 benexate Drugs 0.000 claims description 4
- 239000000440 bentonite Substances 0.000 claims description 4
- 229910000278 bentonite Inorganic materials 0.000 claims description 4
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 235000010980 cellulose Nutrition 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- IAXUQWSLRKIRFR-SAABIXHNSA-N chembl2104696 Chemical compound C1C[C@@H](CNC(=N)N)CC[C@@H]1C(=O)OC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 IAXUQWSLRKIRFR-SAABIXHNSA-N 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 235000012907 honey Nutrition 0.000 claims description 4
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 235000019426 modified starch Nutrition 0.000 claims description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 239000002002 slurry Substances 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 235000010654 Melissa officinalis Nutrition 0.000 claims description 2
- 244000062730 Melissa officinalis Species 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000010692 aromatic oil Substances 0.000 claims description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 2
- 239000008116 calcium stearate Substances 0.000 claims description 2
- 235000013539 calcium stearate Nutrition 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 235000013877 carbamide Nutrition 0.000 claims description 2
- 239000007766 cera flava Substances 0.000 claims description 2
- 230000008859 change Effects 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 2
- 229940059904 light mineral oil Drugs 0.000 claims description 2
- 239000000865 liniment Substances 0.000 claims description 2
- 229940057995 liquid paraffin Drugs 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 239000001194 polyoxyethylene (40) stearate Substances 0.000 claims description 2
- 235000011185 polyoxyethylene (40) stearate Nutrition 0.000 claims description 2
- 230000014860 sensory perception of taste Effects 0.000 claims description 2
- 229940083466 soybean lecithin Drugs 0.000 claims description 2
- 235000013599 spices Nutrition 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- 239000001993 wax Substances 0.000 claims description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims description 2
- 244000287680 Garcinia dulcis Species 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 230000006870 function Effects 0.000 abstract description 12
- 208000002193 Pain Diseases 0.000 abstract description 5
- 241000894006 Bacteria Species 0.000 abstract description 4
- 240000009138 Curcuma zedoaria Species 0.000 abstract description 2
- 235000003405 Curcuma zedoaria Nutrition 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 abstract description 2
- 235000019509 white turmeric Nutrition 0.000 abstract description 2
- 239000003242 anti bacterial agent Substances 0.000 abstract 2
- 229940088710 antibiotic agent Drugs 0.000 abstract 2
- 239000009849 Bupleurum root extract Substances 0.000 abstract 1
- 241000576429 Forsythia suspensa Species 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000010681 turmeric oil Substances 0.000 abstract 1
- 206010022000 influenza Diseases 0.000 description 14
- 230000003115 biocidal effect Effects 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 238000002481 ethanol extraction Methods 0.000 description 9
- 230000003110 anti-inflammatory effect Effects 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 230000000840 anti-viral effect Effects 0.000 description 6
- 230000002155 anti-virotic effect Effects 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 238000005057 refrigeration Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 5
- 230000001754 anti-pyretic effect Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 201000009240 nasopharyngitis Diseases 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000003443 antiviral agent Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000012567 medical material Substances 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 3
- 102100034279 Calcium-binding mitochondrial carrier protein Aralar2 Human genes 0.000 description 3
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 3
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 3
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 3
- 108010084210 citrin Proteins 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229940100243 oleanolic acid Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 230000008728 vascular permeability Effects 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- QRMPRVXWPCLVNI-UHFFFAOYSA-N Curcumenol Natural products C1C(=C)C2CCC(C)C22CC(C(C)C)C1(O)O2 QRMPRVXWPCLVNI-UHFFFAOYSA-N 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 208000031814 IgA Vasculitis Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000207834 Oleaceae Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000001775 anti-pathogenic effect Effects 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- ISFMXVMWEWLJGJ-NZBPQXDJSA-N curcumenol Chemical compound CC1=C[C@](O2)(O)C(=C(C)C)C[C@@]22[C@@H](C)CC[C@H]21 ISFMXVMWEWLJGJ-NZBPQXDJSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a compound bupleurum root soft capsule oral medicine preparation. The medicine contains bupleurum root extract, zedoary turmeric oil and weeping forsythia extract. The medicine preparation comprises tablets, hard capsules, soft capsules, dripping pills, oral liquid and injections. The compound bupleurum root soft capsule oral medicine preparation has the advantages that the compound bupleurum root soft capsule oral medicine preparation is a patent medicine with a new prescription, and compared with other pure Chinese medicine varieties sold on the market, the compound bupleurum root soft capsule oral medicine preparation has the functions for resisting viruses, resisting bacteria, clearing heat and relieving pain, and has complete functions. The compound bupleurum root soft capsule oral medicine preparation does not contain western medicine ingredients, especially does not contain antibiotics, and can avoid side effects due to the excess use of antibiotics.
Description
Technical field
The present invention relates to a kind of Chinese medicine, be specifically related to a kind of compound bupleurum root medicinal preparation, be mainly used in the treatment of upper respiratory tract infection etc. with antiviral, antiinflammatory and antipyretic effect.
Background technology
The cause of disease of flu is comparatively complicated, and the common cold treatment medicine of Xiao Shouing has kind more than 50 in the market, adds different with medicine different name and various dosage forms always to have the medicine that the treatment of kind more than 100 is caught a cold.The medication of traditional treatment flu, doctor's more options antiviral drugs and ntipyretic analgesic medicine are main.Along with the hospitalize development of technology, it is found that the compound preparation of forming by ntipyretic analgesic medicine and antiviral drugs, common cold treatment is had more specific aim, better efficacy.
Recently, investigation shows to the use of coldrex tendency in professional institution, and the compound prescription of being made up of antipyretic analgesic and antiviral agents as " KUAIKE " etc., becomes doctors' at first medicine, and selection rate is up to 48%.The selection purpose of common cold treatment medicine has shown the transformation of current clinical treatment flu disease on method.Shown that doctors more and more tend to the new approaches of the symptomatic treatment of working along both lines from antipyretic-antalgic and antiviral two aspects.
Radix Bupleuri all has the trivial solution heat effect to the heating that multiple reason causes.At anti-virus aspect, Radix Bupleuri removes the inhibition hemophilus influenza, Diplococcus pneumoniae, outside the bacterium effect of golden yellow Portugal, to escherichia coli, bacillus pyocyaneus, dysentery bacterium also have strong inhibitory action, so Radix Bupleuri not only can be applied to treat influenza, the multiple infectious diseases such as caused various infection mumps, pneumonia, acute bronchitis of catching a cold all there is therapeutical effect.
Radix Bupleuri is used for the treatment of flu the beginning sees Shennong's Herbal, all on the books from Qin Han to the medical science works in bright clear each period.In recent years, many scholars have done a large amount of research work to Radix Bupleuri, and have obtained gratifying achievement, prove that Radix Bupleuri can alleviate cold symptoms comprehensively.Summary is got up, and Radix Bupleuri has following five effects greatly: 1) refrigeration function; 2) antibiosis and antiviral functions; 3) analgesic activity; 4) antitussive effect; 5) immune dual regulation.
Rhizoma Curcumae is zingiberaceous plant Rhizoma Curcumae, Radix Curcumae or Guangxi zedoary rhizome.Acrid in the mouth, hardship, warm in nature have the effect of circulation of qi promoting removing blood stasis with potent drugs, removing food stagnancy pain relieving.Diseases such as the stagnant distending pain of main clinically treatment, abdominal pain due to blood stasis, hepatosplenomegaly, amenorrhea due to stagnation of blood, traumatic injury.Modern study, the chemical constituent of Rhizoma Curcumae mainly contains volatile oil, and its composition is Rhizoma Curcumae furan alkene copper, Borneolum Syntheticum, curcumenol etc.Oleum Curcumae has the effect of promoting flow of QI and blood, removing food stagnancy pain relieving, blood circulation promoting and blood stasis dispelling, removing the necrotic tissue and promoting granulation, enhancing human body immunity ability.Modern pharmacological research shows: Oleum Curcumae has: 1) antibacterial action; 2) antiinflammatory action; 3) antivirus action.The antiviral drugs that with the Oleum Curcumae is main component at present is extensive use of clinically.
Fructus Forsythiae is the fruit of Oleaceae plant Fructus Forsythiae, has that heat-clearing and toxic substances removing, removing heat from blood purge heat, the function of dispersing swelling and dissipating binds.Be mainly used in febricity body constitution and interior-heat syndrome.The traditional Chinese medical science is thought, its cold nature, bitter in the mouth, the function heat-clearing and toxic substances removing, mass dissipating and swelling eliminating, be applicable to warm, erysipelas, macule, carbuncle and ulcer toxic swelling and anaphylactoid purpura etc." herbal classic ": " main cold and heat, scrofula, scrofula, carbuncle, malignant boil, goiter, stagnation of pathogenic heat, diseases due to noxious agents produced by various parasites." " Japan hanako materia medica ": " control the furuncle pain relieving." " pearl sac ": " usefulness of Fructus Forsythiae has three: removing pathogen in the heart is through exopathogenic heat, and one also; Go all heat of the part of the body cavity above the diaphragm housing the heart and lungs, two also; Be persons particularly liable to develop skin infection's panacea, three also.”
Fructus Forsythiae contains triterpenoid saponin, and peel contains sterol, phenolic constituent (forsythol), alkaloid, Saponin, oleanolic acid, Coumarins, also has abundant Citrin and a small amount of volatile oil.Fructus Forsythiae has broad-spectrum antibacterial action, and staphylococcus aureus, Hayes dysentery bacterium are had very strong inhibitory action, and other pathogenic bacterium, influenza virus, fungus are all had certain inhibitory action, and contained forsythol is main antipathogenic composition; Antiinflammatory action is arranged; The contained oleanolic acid of Fructus Forsythiae has heart tonifying, diuresis and hypotensive activity; Citrin can reduce vascular permeability and fragility, prevents haemolysis.Decoct has town's effect of telling, anti-liver injury effect.Modern pharmacological research shows that Fructus Forsythiae has: 1) antibacterial action; 2) antiinflammatory action; 3) the refrigeration function decoct that experiment showed, Fructus Forsythiae has refrigeration function to the rabbit of artificial fever.
Comprehensive above-mentioned situation, Radix Bupleuri all has the trivial solution heat effect to the heating that multiple reason causes.The material base of Radix Bupleuri refrigeration function is saikoside and volatile oil, has refrigeration function, antibiosis and antiviral functions, analgesic activity, antitussive effect, immune dual regulation; The chemical constituent of Rhizoma Curcumae mainly contains volatile oil, and Oleum Curcumae has: antibacterial action, antiinflammatory action, antivirus action; Be rich in forsythol, oleanolic acid, Citrin in the Fructus Forsythiae, have: effects such as antibacterial action, antiinflammatory action, refrigeration function, reduction vascular permeability.
Summary of the invention
The object of the present invention is to provide a kind of compound bupleurum root medicinal preparation, be used for the treatment of flu, influenza particularly demonstrates fully the therapeutical effect of prescription in the flu of antipyretic-antalgic, antibiotic, antiinflammatory, anti-virus aspect.
Technical scheme of the present invention is: a kind of compound bupleurum root medicinal preparation, it comprises Radix Bupleuri, Fructus Forsythiae, Rhizoma Curcumae.
Radix Bupleuri in the described medicine is the extract from the Radix Bupleuri that feeds intake in proportion, described Fructus Forsythiae is the extract from the Fructus Forsythiae that feeds intake in proportion, the Oleum Curcumae of described Rhizoma Curcumae for extracting from the Rhizoma Curcumae that feeds intake in proportion, the weight ratio that feeds intake of described raw material is a Radix Bupleuri: Fructus Forsythiae: Rhizoma Curcumae=1: 2～4: 1.5～3.
Described compound bupleurum root medicinal preparation comprises tablet, hard capsule, soft capsule, granule, drop pill, oral liquid and injection.
Oleum Curcumae has antivirus action, and Radix Bupleuri has antipyretic effect, and Fructus Forsythiae has antiinflammatory action.Three's 5 usefulness are used for the treatment of viral influenza and bacillary flu, and it is viral or bacillary not needing dialectical differentiation flu, and can prevent concurrent bacterial infection of viral influenza later stage.Owing to being pure Chinese medicinal preparation thereby having avoided antibiotic use, especially infantile common cold is suitable for the fever symptom.
The present invention compared with prior art has following advantage:
1, do not contain western medicine composition, especially do not contain antibiotic, can avoid antibiotic too much to use and the side effect of generation.
2 compare with other pure herbal species that gone on the market, have antiviral, antibiotic and antipyretic effect simultaneously, and effect comprehensively.
3, to carry out with the mice be the pharmacodynamics test of object in the present invention, and proving has tangible antipyretic effect to the caused fever of viral influenza, and antibiotic, disease-resistant degree effect is remarkable.
The specific embodiment
A kind of compound bupleurum root medicinal preparation, it comprises Radix Bupleuri, Fructus Forsythiae, Rhizoma Curcumae.
Radix Bupleuri in the described medicine is the extract of the Radix Bupleuri that feeds intake in proportion, described Fructus Forsythiae is the extract of the Fructus Forsythiae that feeds intake in proportion, the Oleum Curcumae of described Rhizoma Curcumae for extracting from the Rhizoma Curcumae that feeds intake in proportion, the weight ratio that feeds intake of the above-mentioned raw material that feeds intake in proportion is a Radix Bupleuri: Fructus Forsythiae: Rhizoma Curcumae=1: 2～4: 1.5～3.
Described Oleum Curcumae is that supercritical CO 2 extraction or steam distillation extract volatile oil.Described Oleum Curcumae is meant the Oleum Curcumae clathrate in tablet, hard capsule, granule, drop pill, comprise Benexate Hydrochloride and hydroxypropyl clathrate.A kind of detailed process of clathrate preparation is as follows: adopt the saturated aqueous solution envelope, Oleum Curcumae: beta-schardinger dextrin-: the proportioning of water is 1mL: 4g: 60mL, and mixing time is 2 hours, obtains the Oleum Curcumae Benexate Hydrochloride.
The extract of Radix Bupleuri extracts according to a conventional method, mainly be medical material with 40～85% ethanol extractions, the medicinal residues decocting is boiled carry out water extraction again, the mixed Radix Bupleuri extract that is of water extract and ethanol extraction.A kind of detailed process wherein is as follows: medical material is with 60% ethanol extraction, extracting solution concentrates, and drying obtains ethanol extraction, and medicinal residues decoct with water secondary, 1 hour for the first time, 45 minutes for the second time, to filter, filtrate merging is evaporated to proportion 1.15～1.20, ethanol precipitate with ethanol with triplication, supernatant concentration is also dry, obtains water extract, the mixed Radix Bupleuri extract that promptly gets of ethanol extraction and water extract.The extract of Fructus Forsythiae extracts according to a conventional method, mainly be medical material with 40～85% ethanol extractions, the medicinal residues decocting boil water extract, the mixed Fructus Forsythiae extract that is of water extract and alcohol extract.A kind of detailed process wherein is as follows: medical material is with 65% ethanol extraction, extracting solution concentrates, drying obtains ethanol extraction, and medicinal residues decoct with water secondary, each 1 hour, filter, filtrate merging is evaporated to proportion 1.15～1.20, and with the ethanol precipitate with ethanol of triplication, supernatant concentration is also dry, obtain water extract, the mixed Fructus Forsythiae extract that promptly gets of ethanol extraction and water extract.
Can make the several formulations type after above Radix Bupleuri extract, Fructus Forsythiae extract and Oleum Curcumae are mixed, comprise that described medicine is an oral administered dosage form, described oral administered dosage form is an oral solid formulation, comprise tablet, soft capsule, hard capsule, granule, drop pill, described oral administered dosage form is an oral liquid, also can be to make injection.
Also comprise excipient in the medicine of described tablet, after described Radix Bupleuri, Fructus Forsythiae, Rhizoma Curcumae and excipient are mixed, be pressed into tablet.
Described excipient is one or more the mixture in wetting agent, binding agent, disintegrating agent, the lubricant.
Wetting agent and binding agent are a kind of or its mixture in distilled water, ethanol, starch slurry, syrup, the refined honey.Disintegrating agent is one or more the mixture in starch, modified starch, cellulose, alginic acid, plant gum, kaolin, aluminium-magnesium silicate, the Bentonite.Lubricant is a kind of or wherein several mixture of stearic acid, calcium stearate, magnesium stearate, zinc stearate, hydrogenated vegetable oil, polyoxyethylene monostearate, light mineral oil, liquid Paraffin, wax apoplexy due to endogenous wind.
After making hard capsule, described medicine is packed in the hard capsule case.
After making soft capsule, also include stabilizing agent and solvent in the described medicine.Described stabilizing agent is a kind of or its mixture in water, glycerol, tween, ethyoxyl castor oil hydrogenated, soybean lecithin, Cera Flava, glyceryl monostearate, ethyl cellulose, solid polyethylene glycol, the PEG400 glyceryl monostearate.
Described solvent is a kind of or its mixture in liquid polyethylene glycol, isopropyl alcohol, tween, span, glycerol, propylene glycol, water, the vegetable oil.
The weight proportion of described medicine is as follows:
The mixture 1 of Radix Bupleuri extract, Fructus Forsythiae extract, Oleum Curcumae
Solvent 1～4
Stabilizing agent 0.01～1.20
Above-mentioned medicine is filled in the softgel shell, makes Oleum Curcumae can not volatilize, and keeps the active ingredient of medicine.
After making granule, also include excipient in the described granule, after described Radix Bupleuri, Fructus Forsythiae, Rhizoma Curcumae and excipient are mixed, make graininess.
Described excipient is one or more in wetting agent, binding agent, the disintegrating agent.
Described wetting agent and binding agent are a kind of or its mixture in distilled water, ethanol, starch slurry, syrup, the refined honey; Described disintegrating agent is a kind of or its mixture in starch, modified starch, cellulose, alginic acid, plant gum, kaolin, aluminium-magnesium silicate, the Bentonite.
After making drop pill, also comprise substrate in the described medicine, described substrate be below 40 ℃ for medicinal substrate stationary state, that can form drop pill, be one or more the mixture in solid polyethylene glycol, polyoxyethylene (40) stearate, poloxamer, carbamide, monostearate, octadecanol, hexadecanol, glyceryl monostearate, the tween.
Oral administered dosage form is an oral liquid, can make oral liquid, also comprises a kind of or its mixture in cosolvent, correctives, the aromatic in the described medicine.
In tablet, hard capsule, granule, drop pill, described Rhizoma Curcumae is meant the Oleum Curcumae clathrate, and described Oleum Curcumae clathrate comprises Benexate Hydrochloride, hydroxypropyl clathrate.
After making injection, also comprise a kind of or its mixture in mixed solvent, the injection non-ionic solubilizer in the described medicine, described mixed solvent comprises water, ethanol, also comprise the mixture of low carbon polyol or Polyethylene Glycol or low carbon polyol and Polyethylene Glycol, described low carbon polyol is meant the mixture of propylene glycol or glycerol or propylene glycol and glycerol; The consumption of described mixed solvent should be enough to make described medicine dissolution and keep stable.Described injection non-ionic solubilizer is one of polyoxyethylene monostearate, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene castor oil or its mixture.
Good effect of the present invention has provided a kind of compound bupleurum root medicinal preparation, product is new prescription patent medicine, Oleum Curcumae has antivirus action, Radix Bupleuri has the analgesic effect of bringing down a fever, Fructus Forsythiae has antibacterial action, and three's 5 usefulness are compared with other pure herbal species that gone on the market, have antiviral, antibiotic and antipyretic effect simultaneously, effect comprehensively.And do not contain western medicine composition, especially do not contain antibiotic, can avoid antibiotic too much to use and the side effect of generation.
Embodiment 1: weight ratio (gram/sheet)
Radix Bupleuri extract 0.09
The Fructus Forsythiae extract corresponding amount
Oleum Curcumae clathrate corresponding amount
Starch is an amount of
Hydroxypropyl cellulose 0.09
Method for making: Oleum Curcumae clathrate and Radix Bupleuri extract, Fructus Forsythiae extract, hydroxypropyl cellulose, starch are mixed evenly, add suitable quantity of water, the system soft material is granulated, and is pressed into the compound bupleuri sheet at last.
Embodiment 2: weight ratio (gram/grain)
Radix Bupleuri extract 0.04
The Fructus Forsythiae extract corresponding amount
Oleum Curcumae clathrate corresponding amount
Starch is an amount of
Microcrystalline Cellulose 0.05
Method for making: Oleum Curcumae clathrate and Radix Bupleuri extract, Fructus Forsythiae extract, microcrystalline Cellulose, starch are mixed evenly, add an amount of water system soft material, granulate, oven dry, granulate pours in the hard capsule case, makes the compound bupleuri hard capsule.
Embodiment 3:
Components by weight (gram/grain)
Radix Bupleuri extract 0.07
The Fructus Forsythiae extract corresponding amount
The Oleum Curcumae corresponding amount
Polyethylene Glycol 0.21
Glycerol 0.035
Capsule shells 0.20
Method for making: extract, the Fructus Forsythiae extract of Radix Bupleuri are beaten powder cross behind 120～200 mesh sieves standby, earlier stabilizing agent and partial solvent heating for dissolving are formed the thermosol thing, again the thermosol thing is joined in the residual solvent that is preheated to 35～55 ℃ lentamente, the limit edged stirs, and adds the fully mixed rear packing of Radix Bupleuri extract, Fructus Forsythiae extract and the Oleum Curcumae pulverized then.Make the compound bupleuri soft capsule.
Embodiment 4: weight ratio (gram/bag)
Radix Bupleuri extract 0.98
The Fructus Forsythiae extract corresponding amount
Oleum Curcumae clathrate corresponding amount
Starch is an amount of
Hydroxypropyl methylcellulose 1.45
Method for making: Oleum Curcumae clathrate and Radix Bupleuri extract, Fructus Forsythiae extract, hydroxypropyl methylcellulose, starch is evenly mixed, add suitable quantity of water, the system soft material is granulated, last granulate, fill promptly gets the compound bupleuri granule in bag.
Embodiment 5:
Radix Bupleuri extract 0.01
The Fructus Forsythiae extract corresponding amount
Oleum Curcumae clathrate corresponding amount
Macrogol 4000 is an amount of
Method for making: taking polyethylene glycol 4000 is heated to molten condition, add Radix Bupleuri extract, Fructus Forsythiae extract in the Macrogol 4000 under molten condition again, continue heating, stir, heat-retaining condition adds the Oleum Curcumae clathrate down, splashes into after stirring and is condensed into ball in the liquid coolant.Make the compound bupleuri drop pill.
Embodiment 6:
Radix Bupleuri extract 0.12
The Fructus Forsythiae extract corresponding amount
The Oleum Curcumae corresponding amount
Tween 80 is an amount of
Propylene glycol 20ml
Correctives 0.1
Water is made 100ml
Method for making: Radix Bupleuri extract, Fructus Forsythiae extract, Oleum Curcumae mix, and add the mixed solvent of being made up of tween 80, propylene glycol, artificial essence and part water, stir and make into the solution shape, add water to full dose, filter, fill is in oral liquid bottle, the compound bupleuri oral liquid is made in sterilization.
Embodiment 7:
Radix Bupleuri extract 0.02
The Fructus Forsythiae extract corresponding amount
The Oleum Curcumae corresponding amount
Tween 80 is an amount of
Propylene glycol 20ml
Water is made 100ml
Method for making: Radix Bupleuri extract, Fructus Forsythiae extract, Oleum Curcumae mix, and add the mixed solvent of being made up of tween 80, propylene glycol and part water, stir and make into the solution shape, add water to full dose, filter, and fill is in ampoule, and the compound bupleuri injection is made in sterilization.
Described oral liquid is an oral liquid, also comprises a kind of or its mixture in cosolvent, correctives, the aromatic in the described oral liquid; Cosolvent is meant it is one of polyoxyethylene monostearate, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene castor oil or its mixture at least; Correctives is meant the material that can change the sense of taste, the taste that is usually used in covering the cacogeusia of medicine in the medicament and improves medicament; Aromatic is meant volatile oil or balm, synthetic spice or its mixture of contained volatile aromatic oil such as fruit, seed, flower, leaf, root, stem and skin after purifying of natural plants.
Claims (26)
1, a kind of compound bupleurum root medicinal preparation, it is characterized in that: the raw material for preparing its active ingredient is made up of Radix Bupleuri, Fructus Forsythiae, Rhizoma Curcumae, the Radix Bupleuri extract of Radix Bupleuri in the described medicine for from the Radix Bupleuri that feeds intake in proportion, extracting, the Fructus Forsythiae extract of described Fructus Forsythiae for from the Fructus Forsythiae that feeds intake in proportion, extracting, the Oleum Curcumae of described Rhizoma Curcumae for extracting from the Rhizoma Curcumae that feeds intake in proportion, the weight ratio that feeds intake of described each raw material is a Radix Bupleuri: Fructus Forsythiae: Rhizoma Curcumae=1: 2～4: 1.5～3.
2, compound bupleurum root medicinal preparation according to claim 1 is characterized in that: described pharmaceutical preparation is oral administered dosage form.
3, compound bupleurum root medicinal preparation according to claim 2 is characterized in that: described oral administered dosage form is an oral solid formulation.
4, compound bupleurum root medicinal preparation according to claim 2 is characterized in that: described oral solid formulation is at least one of tablet, hard capsule, soft capsule, granule, drop pill.
5, compound bupleurum root medicinal preparation according to claim 4 is characterized in that: also comprise excipient in the medicine of described tablet.
6, compound bupleurum root medicinal preparation according to claim 5 is characterized in that: after described Radix Bupleuri, Fructus Forsythiae, Rhizoma Curcumae and excipient are mixed, be pressed into tablet.
7, compound bupleurum root medicinal preparation according to claim 5 is characterized in that: described excipient is one or more the mixture in wetting agent, binding agent, disintegrating agent, the lubricant.
8, compound bupleurum root medicinal preparation according to claim 7 is characterized in that: described wetting agent and binding agent are one or more the mixture in distilled water, ethanol, starch slurry, syrup, the refined honey; Described disintegrating agent is one or more the mixture in starch, modified starch, cellulose, alginic acid, plant gum, kaolin, aluminium-magnesium silicate, the Bentonite; Described lubricant is a kind of or wherein several mixture of stearic acid, calcium stearate, magnesium stearate, zinc stearate, hydrogenated vegetable oil, polyoxyethylene monostearate, light mineral oil, liquid Paraffin, wax apoplexy due to endogenous wind.
9, compound bupleurum root medicinal preparation according to claim 4 is characterized in that: in described hard capsule, described medicine is filled in the hard capsule.
10, compound bupleurum root medicinal preparation according to claim 4 is characterized in that: also include stabilizing agent and solvent in the medicine of described soft capsule, and described medicine is loaded in the softgel shell.
11, compound bupleurum root medicinal preparation according to claim 10 is characterized in that: the weight proportion of described medicine is as follows;
The pro rata mixture 1 of Radix Bupleuri extract, Fructus Forsythiae extract, Oleum Curcumae
Solvent 1～4
Stabilizing agent 0.01～1.20
12, compound bupleurum root medicinal preparation according to claim 10 is characterized in that: described stabilizing agent is a kind of or its mixture in water, glycerol, tween, ethyoxyl castor oil hydrogenated, soybean lecithin, Cera Flava, glyceryl monostearate, ethyl cellulose, solid polyethylene glycol, the PEG400 glyceryl monostearate; Described solvent is a kind of or its mixture in liquid polyethylene glycol, isopropyl alcohol, tween, span, glycerol, propylene glycol, water, the vegetable oil.
13, compound bupleurum root medicinal preparation according to claim 4 is characterized in that: also include excipient in the described granule.
14, compound bupleurum root medicinal preparation according to claim 13 is characterized in that: after described Radix Bupleuri, Fructus Forsythiae, Rhizoma Curcumae and excipient are mixed, make graininess.
15, compound bupleurum root medicinal preparation according to claim 13 is characterized in that: described excipient is one or more in wetting agent, binding agent, the disintegrating agent.
16, compound bupleurum root medicinal preparation according to claim 15 is characterized in that: described wetting agent and binding agent are a kind of or its mixture in distilled water, ethanol, starch slurry, syrup, the refined honey; Described disintegrating agent is a kind of or its mixture in starch, modified starch, cellulose, alginic acid, plant gum, kaolin, aluminium-magnesium silicate, the Bentonite.
17, compound bupleurum root medicinal preparation according to claim 4 is characterized in that: also include substrate in the medicine of described drop pill.
18, compound bupleurum root medicinal preparation according to claim 17, it is characterized in that: described substrate is to be under the room temperature condition below 40 ℃ to be a kind of or its mixture in solid polyethylene glycol, polyoxyethylene (40) stearate, poloxamer, carbamide, monostearate, octadecanol, hexadecanol, glyceryl monostearate, the tween by medicinal substrate stationary state, that can form drop pill.
19, compound bupleurum root medicinal preparation according to claim 4 is characterized in that: in tablet, hard capsule, granule, drop pill, described Rhizoma Curcumae is meant the Oleum Curcumae clathrate.
20, compound bupleurum root medicinal preparation according to claim 19 is characterized in that: described Oleum Curcumae clathrate comprises Benexate Hydrochloride, hydroxypropyl clathrate.
21, compound bupleurum root medicinal preparation according to claim 2 is characterized in that: described oral administered dosage form is an oral liquid.
22, compound bupleurum root medicinal preparation according to claim 21 is characterized in that: described oral liquid is an oral liquid.
23, compound bupleurum root medicinal preparation according to claim 22 is characterized in that: also comprise a kind of or its mixture in cosolvent, correctives, the aromatic in the described oral liquid; Cosolvent is meant it is one of polyoxyethylene monostearate, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene castor oil or its mixture at least; Correctives is meant the material that can change the sense of taste, the taste that is usually used in covering the cacogeusia of medicine in the medicament and improves medicament; Aromatic is meant volatile oil or balm, synthetic spice or its mixture of contained volatile aromatic oil such as fruit, seed, flower, leaf, root, stem and skin after purifying of natural plants.
24, compound bupleurum root medicinal preparation according to claim 1 is characterized in that: described medicine is an injecting medicine-feeding form.
25, compound bupleurum root medicinal preparation according to claim 24 is characterized in that: also comprise a kind of or its mixture in mixed solvent, the injection non-ionic solubilizer in the described medicine.
26, compound bupleurum root medicinal preparation according to claim 25, it is characterized in that: described mixed solvent comprises water, ethanol, described mixed solvent also comprises low carbon polyol, one of Polyethylene Glycol or both mixture, described low carbon polyol is meant propylene glycol, the mixture of one of glycerol or propylene glycol and glycerol, the consumption of described mixed solvent should be enough to make and comprises Radix Bupleuri, Fructus Forsythiae, the medicine dissolution of Rhizoma Curcumae also keeps stable, and described injection non-ionic solubilizer is to be polyoxyethylene monostearate at least, polyoxyethylene sorbitan fatty acid ester, one of polyoxyethylene castor oil or its mixture.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410065122 CN1278731C (en) | 2004-10-22 | 2004-10-22 | Compound bupleurum root medicinal preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410065122 CN1278731C (en) | 2004-10-22 | 2004-10-22 | Compound bupleurum root medicinal preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1634330A CN1634330A (en) | 2005-07-06 |
| CN1278731C true CN1278731C (en) | 2006-10-11 |
Family
ID=34846441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410065122 Expired - Lifetime CN1278731C (en) | 2004-10-22 | 2004-10-22 | Compound bupleurum root medicinal preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1278731C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100444734C (en) * | 2005-11-08 | 2008-12-24 | 广州暨南大学医药生物技术研究开发中心 | A compound antivirus sprayer and preparation method thereof |
| CN100404064C (en) * | 2006-03-02 | 2008-07-23 | 成都厚发科技开发有限公司 | Medicine composition having functions of resisting virus and clearing heat and preparing method |
| CN113425694A (en) * | 2021-07-02 | 2021-09-24 | 杭州蚕宝生物技术有限公司 | Dendrobium alkaloid orally disintegrating tablet and preparation method thereof |
| CN117530917B (en) * | 2024-01-09 | 2024-04-05 | 北京中科利华医药研究院有限公司 | Bupleurum root suppository |
-
2004
- 2004-10-22 CN CN 200410065122 patent/CN1278731C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1634330A (en) | 2005-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102225138B (en) | Traditional Chinese medicine composition for treating fracture and preparation method and application thereof | |
| CN100350900C (en) | Diphase capsule of compound dalbergia wood and preparation method | |
| CN1278731C (en) | Compound bupleurum root medicinal preparation | |
| CN1698820A (en) | Dripping pills with jaundice eliminating liver protecting functions and its preparation method | |
| CN100350899C (en) | Diphase capsule of red sage root for coronary heart disease and preparation method | |
| CN100350898C (en) | Diphase capsule of compound notoginseng and preparation method | |
| CN1720948A (en) | Dripping pills of lllicium henryi dripping pills and method for preparing the same | |
| CN1879701A (en) | Cold-treating medicine and preparation method thereof | |
| CN1233401C (en) | Agastache capsule for restoring healthy energy andits prepn and application | |
| CN1814188A (en) | Vitaminc lonicera and forsythia capsule and preparing method | |
| CN1931279A (en) | Medicine for treating biliary tract infection and its prepn process | |
| CN1689637A (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN100375616C (en) | Bone strengthening dripping pills with Premena fulva craib as raw material and method for preparing the same | |
| CN100542517C (en) | Calculus bovis detoxifying dropping pill and preparation method thereof | |
| CN1748741A (en) | Little leaf deervetch herb acne removing preparation and new preparing method | |
| CN1682819A (en) | Sihuang intense heat purging dripping pill and its preparing method | |
| CN1718225A (en) | Compound traditional Chinese medicine for treating hepatic lesion, and its prepn. method | |
| CN1682821A (en) | Compound radical lobelia dripping pill and its preparing method | |
| CN1260204A (en) | Medicament for treating diabetes and its preparation method | |
| CN100348171C (en) | Yujin drop pill for clearing away the heat-evil and expelling superficial evils and its preparation method | |
| CN1840063A (en) | Dripping pills of 'Da Yuan Yin' and preparation method thereof | |
| CN1872219A (en) | Soft capsule for treating headache, and preparation method | |
| CN1720950A (en) | Compound drop pills of Chinese angelica and its preparation method | |
| CN1118278C (en) | Application of ursolic acid in medicine for treating viral hepatitis | |
| CN105106817A (en) | Yao medicine compound broadleaf globethistle inflorescence tablet for treating diabetes and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: JIANGSU WUZHONG MEDICINE GROUP CO., LTD. Free format text: FORMER OWNER: JIANGSU WUZHONG CHINESE MEDICINE RESEARCH AND DEVELOPMENT CO., LTD. Effective date: 20091030 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20091030 Address after: 8, No. 2 Wu Dong South Road, Jiangsu, Suzhou Patentee after: Jiangsu Wuzhong Medical Group Co.,Ltd. Address before: No. 2, Soochow South Road, Jiangsu, Suzhou Patentee before: Wuzhong Chinese Medicines Research & Development Co., Ltd., Jiangsu |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160918 Address after: 215168, No. 2, Soochow South Road, Suzhou, Jiangsu, 8 Patentee after: Jiangsu Wuzhong Medical Group Co.,Ltd. Patentee after: Jiangsu Wuzhong Pharmaceutical Group Co., Ltd. Suzhou pharmaceutical factory Address before: 215168, No. 2, Soochow South Road, Suzhou, Jiangsu, 8 Patentee before: Jiangsu Wuzhong Medical Group Co.,Ltd. |